Sino-Japanese Journalist Exchange Agreement

AgeX Therapeutics Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 14, 2023
Research, Other Health, Pharmaceutical, Consumer Electronics, Consumer, Technology, Science, Biotechnology, Stem Cells, Seniors, Health, Diabetes, Other Science, Sale, Classification, NYSE, AgeX Therapeutics, Therapy, Preferred stock, Regeneration, Bank statement, Security agreement, Agreement, ASC, Accounting standard, Exchange, GAAP, Private law, Finance, Ageing, Security, Plan, Sino-Japanese Journalist Exchange Agreement, Pharmaceutical industry, Security (finance)

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter and nine months ended September 30, 2023.

Key Points: 
  • AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter and nine months ended September 30, 2023.
  • On October 31, 2023, AgeX made a final draw of loan funds available under a line of credit from Juvenescence Limited.
  • Cash, cash equivalents, and restricted cash totaled $0.4 million as of September 30, 2023.
  • These factors raise substantial doubt regarding the ability of AgeX to continue as a going concern.

Sarepta Therapeutics Announces Third Quarter 2023 Financial Results and Recent Corporate Developments

Retrieved on: 
Wednesday, November 1, 2023
Biotechnology, FDA, Pharmaceutical, Health, Sino-Japanese Journalist Exchange Agreement, Priority review, Research, Sale, LGMD, Hart–Scott–Rodino Antitrust Improvements Act, PMOS, Patent, Food, PIN, Rare, RNA, GAAP, PRV, SRPT, Acquisition, Holocene, Sarepta Therapeutics, Food and Drug Administration, Disease, Interest, Clinical trial, Duchenne, Duchenne muscular dystrophy, University, Nationwide Children's Hospital, Depreciation, Leyland Royal Tiger PSU, BioMarin Pharmaceutical, Therapy, Investment, Patient, Hospital, Pharmaceutical industry, Reinsurance, Cryptocurrency, Fine chemical, Rare-earth element, Airline, Property management, Bank, Real estate, Life insurance, Note

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter 2023.

Key Points: 
  • Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter 2023.
  • Total net product revenue stands at $309.3 million, growing 49 percent over the same quarter last year.
  • These non-GAAP measures are not intended to be considered in isolation or to replace the presentation of the Company’s financial results in accordance with GAAP.
  • All relevant non-GAAP measures are reconciled from their respective GAAP measures in the attached table “Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures.”

Argentina Lithium Announces US$90 Million Investment by Stellantis in ARS$ Equivalent

Retrieved on: 
Wednesday, September 27, 2023
Lithium, Sino-Japanese Journalist Exchange Agreement, Exercise, LLP, Shareholder, PI, ARS, Abarth, Peugeot, Car, Dodge, FSE, Exchange, Fiat, IRA, Sale, Opel, Certification, International investment agreement, Lancia, Maserati, Acquisition, Alfa Romeo, RAM, Environmental Defense v. Duke Energy Corp., OTC, Transaction, Indian stock exchange, ALE, Liverpool Offtake Reservoir, DS Automobiles, Chrysler, Transport, Holding company, Security (finance), Real estate, Stellantis, Leasi Papali'i Tommy Scanlan

As a result of the Transaction, Stellantis will own 19.9% of the issued and outstanding ALE Shares and Argentina Lithium will own 80.1%.

Key Points: 
  • As a result of the Transaction, Stellantis will own 19.9% of the issued and outstanding ALE Shares and Argentina Lithium will own 80.1%.
  • Argentina Lithium President & Chief Executive Officer Nikolaos Cacos said: "We are delighted to have Stellantis as a partner in the future development of our lithium projects in Argentina.
  • At closing of the Transaction, Argentina Lithium and Stellantis will enter into an exchange agreement (the "Exchange Agreement").
  • In addition, upon exercise of the Exchange Right, Argentina Lithium will enter into an Investor Rights Agreement with Stellantis (the "Stellantis IRA").

AgeX Therapeutics Reports Second Quarter 2023 Financial Results

Retrieved on: 
Monday, August 14, 2023
Research, Seniors, Diabetes, Stem Cells, Biotechnology, Health, Consumer, Pharmaceutical, Science, External commercial borrowing, AgeX Therapeutics, Sino-Japanese Journalist Exchange Agreement, ASC, Interim, Tuck School of Business, Therapy, Private law, Bank statement, Audit committee, Ageing, Business, Accounting standard, Exchange, MBA, Finance, Separation, Regeneration, The Sovereign Fund of Egypt, Dartmouth University, Employment, Pre-consultation Agreement (Japan), NYSE, Compensated emancipation, Edmonton Transit Service, Pharmaceutical industry, Cryptocurrency, Security (finance), Management, MD

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter and six months ended June 30, 2023.

Key Points: 
  • AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter and six months ended June 30, 2023.
  • Cash, cash equivalents, and restricted cash totaled $0.3 million as of June 30, 2023.
  • As of June 30, 2023, AgeX owed Juvenescence Limited (“Juvenescence”) $33 million in principal and origination fees on account of loans extended to AgeX.
  • Operating expenses: Operating expenses for the three months ended June 30, 2023 were $1.9 million, as compared with $1.6 million for the same period in 2022.

RYVYL Announces Completion of Initial Steps Under the Exchange Agreement Reducing Debt and Increasing Shareholder Equity and Cash Flow

Retrieved on: 
Thursday, August 3, 2023
Sino-Japanese Journalist Exchange Agreement, Blockchain, Note, Bangladesh Securities and Exchange Commission, SAN, Security (finance), Cryptocurrency

SAN DIEGO, CA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- RYVYL Inc. (NASDAQ: RVYL) ("RYVYL" or the "Company"), a company that leverages the security of the blockchain and USD-pegged stablecoin technology with near-real-time attestation capabilities to conduct payment transactions, announced today the Company on July 31, 2023 closed the first of two exchange transactions, with an existing noteholder (the “Noteholder”) under the terms of an Exchange Agreement, dated July 25, 2023 (the “Exchange Agreement”), and issued 6,000 shares of Series A Convertible Preferred Stock to the Noteholder in exchange for $4,297,000 of the outstanding principal balance of the Note and $1,703,000 of accrued interest.

Key Points: 
  • SAN DIEGO, CA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- RYVYL Inc. (NASDAQ: RVYL) ("RYVYL" or the "Company"), a company that leverages the security of the blockchain and USD-pegged stablecoin technology with near-real-time attestation capabilities to conduct payment transactions, announced today the Company on July 31, 2023 closed the first of two exchange transactions, with an existing noteholder (the “Noteholder”) under the terms of an Exchange Agreement, dated July 25, 2023 (the “Exchange Agreement”), and issued 6,000 shares of Series A Convertible Preferred Stock to the Noteholder in exchange for $4,297,000 of the outstanding principal balance of the Note and $1,703,000 of accrued interest.
  • As recently announced in a July 26, 2023 press release , under the terms of the Exchange Agreement, the Company and the Noteholder agreed to exchange, in two separate exchanges, an aggregate of $22.703 million of the outstanding principal and interest under an outstanding convertible note, held by the Noteholder, for 15,000 shares of the Company’s s Series A Preferred Convertible Stock .
  • The remaining $16,703,000 in principal, not closed on, under the terms of the Exchange Agreement, is to be exchanged for 9,000 shares of Series A Convertible Preferred Stock at an additional closing, subject to the Company’s having satisfied certain conditions, including obtaining stockholder approval for the issuance of all shares of common stock underlying the Series A Convertible Preferred Stock, in accordance with the rules and regulations of NASDAQ.
  • Additional information can be found in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 1, 2023, and available on RYVYL’s Investor Relations website https://investors.ryvyl.com/financials/sec-filings/

Sarepta Therapeutics Announces Second Quarter 2023 Financial Results and Recent Corporate Developments

Retrieved on: 
Wednesday, August 2, 2023
Biotechnology, Other Health, Health, Genetics, Pharmaceutical, Nationwide Children's Hospital, Week, BioMarin Pharmaceutical, Food and Drug Administration, GAAP, Interest, University, Acquisition, Patent, Thermo Fisher Scientific, Patient, Investment, Leyland Royal Tiger PSU, Duchenne muscular dystrophy, Priority review, Mutation, Sino-Japanese Journalist Exchange Agreement, Research, Muscular dystrophy, Hart–Scott–Rodino Antitrust Improvements Act, Hospital, PMO, Rare, FDA, Safety, Advisory Committee, PUL, SRPT, Commencement at Central Connecticut State University, PIN, Depreciation, Therapy, PRV, Probability, Clinical trial, Part, RNA, Sale, Thermo, DMD, Food, Pharmaceutical industry, Health insurance, Reinsurance, Cryptocurrency, Fine chemical, Rare-earth element, Construction, Security (finance), Real estate, Bank, Duchenne, Note

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter 2023.

Key Points: 
  • Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter 2023.
  • Sarepta was awarded the PRV following U.S. Food and Drug Administration (FDA) accelerated approval of ELEVIDYS (delandistrogene moxeparvovec-rokl).
  • These non-GAAP measures are not intended to be considered in isolation or to replace the presentation of the Company’s financial results in accordance with GAAP.
  • All relevant non-GAAP measures are reconciled from their respective GAAP measures in the attached table “Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures.”

RYVYL Bolsters Capital Structure Resulting in Debt Reduction, Significant Improvement to Cash Flow, and Increased Shareholder Equity in Exchange Agreement with Convertible Noteholder

Retrieved on: 
Wednesday, July 26, 2023
Sino-Japanese Journalist Exchange Agreement, Blockchain, Risk, SAN, Security (finance)

SAN DIEGO, CA, July 26, 2023 (GLOBE NEWSWIRE) -- RYVYL Inc. (NASDAQ: RVYL) ("RYVYL" or the "Company"), a company that leverages the security of the blockchain and USD-pegged stablecoin technology with near-real-time attestation capabilities to conduct payment transactions, has agreed to an amendment of terms with the noteholder of the $100 million convertible note financing, originally entered into on November 5, 2021.

Key Points: 
  • Under the terms of an Exchange Agreement, in two separate exchanges, an aggregate of $22.703 million of the existing note will potentially be exchanged into 15,000 shares of a new class of RYVYL convertible preferred stock, with an aggregate stated value of $15,000,000.
  • Under the terms of the separate Leak-Out Agreement with the noteholder, there are also certain limitations on the noteholder’s sales of RVYL stock in the open market.
  • We believe that the exchange should significantly bolster and revitalize our capital structure with the added benefit of mitigating NASDAQ compliance deficiencies risk on both bid price compliance and future shareholder equity requirements.
  • We are grateful to have this institutional level commitment to our global growth capabilities.”

AgeX Therapeutics Closes $36,000,000 Debt Exchange for Preferred Stock

Retrieved on: 
Monday, July 24, 2023
Stem Cells, Biotechnology, Other Retail, Alternative Medicine, Other Health, Diabetes, Health, Pharmaceutical, Other Science, Retail, Science, AgeX Therapeutics, Sino-Japanese Journalist Exchange Agreement, NYSE American, Therapy, Ageing, Preferred stock, Exchange, Consultant, Sale, Regeneration, Hearing, Delaware General Corporation Law, NYSE, Security (finance)

The cancellation of indebtedness in exchange for the Preferred Stock was conducted pursuant to an Exchange Agreement between AgeX and Juvenescence.

Key Points: 
  • The cancellation of indebtedness in exchange for the Preferred Stock was conducted pursuant to an Exchange Agreement between AgeX and Juvenescence.
  • By completing the exchange of indebtedness for shares of Series A Preferred Stock and Series B Preferred Stock (collectively referred to as the “Preferred Stock”), AgeX now has sufficient stockholders equity to meet the NYSE American continued listing requirements.
  • The subscription price per share of Preferred Stock is $100 which was paid through the exchange of indebtedness for shares of Preferred Stock.
  • The conversion price per share of Series A Preferred Stock or Series B Preferred Stock is $0.72 which was the closing price of AgeX common stock on the NYSE American on the last trading day immediately preceding the execution of the Exchange Agreement.

AgeX Therapeutics Announces $36,000,000 Debt Exchange for Preferred Stock

Retrieved on: 
Friday, July 21, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Alternative Medicine, Health, Diabetes, AgeX Therapeutics, Sino-Japanese Journalist Exchange Agreement, State, Therapy, Ageing, Preferred stock, Exchange, Consultant, Sale, Regeneration, NYSE American, Delaware General Corporation Law, NYSE, Security (finance), Series

The exchange of the indebtedness for shares of Series A Preferred Stock and Series B Preferred Stock (collectively referred to as the “Preferred Stock”) will be implemented for the purpose of bringing AgeX common stock back into compliance with the continued listing requirements of the NYSE American that require AgeX to have at least $6 Million of stockholders equity; however the continued listing remains dependent upon a determination by the NYSE American that AgeX has regained compliance with their listing standards.

Key Points: 
  • The exchange of the indebtedness for shares of Series A Preferred Stock and Series B Preferred Stock (collectively referred to as the “Preferred Stock”) will be implemented for the purpose of bringing AgeX common stock back into compliance with the continued listing requirements of the NYSE American that require AgeX to have at least $6 Million of stockholders equity; however the continued listing remains dependent upon a determination by the NYSE American that AgeX has regained compliance with their listing standards.
  • The consummation of the exchange of indebtedness for Preferred Stock is expected to occur on or around July 25, 2023 subject to (a) the NYSE American approving a supplemental application to list the common stock issuable upon conversion of the Preferred Stock into common stock, and (b) the filing of a Certificate of Designation of the Series A Preferred Stock and a Certificate of Designation of the Series B Preferred Stock with the Secretary of State of Delaware.
  • The subscription price per share of Preferred Stock is $100 which was paid through the exchange of indebtedness for shares of Preferred Stock.
  • The conversion price per share of Series A Preferred Stock or Series B Preferred Stock is $0.72 which was the closing price of AgeX common stock on the NYSE American on the last trading day immediately preceding the execution of the Exchange Agreement.

Stronghold Digital Mining Reports First Quarter 2023 Results and Provides Operational Update

Retrieved on: 
Thursday, May 11, 2023
Common stock, Maintenance, Sino-Japanese Journalist Exchange Agreement, Minerva, PJM, Canaan, Miner, Exchange, Common, Kilowatt-hour, Coal, Traction, Whitehawk, Panther Creek, Investment, Mining, Tobacco Master Settlement Agreement, Adjustment, Environment, Credit, SDIG, Economics, Earnings call, Cryptocurrency, Security (finance), Note, Bitcoin, The Box

Stronghold continues to vigilantly manage its exposure to counterparties exposed to the cryptocurrency and technology sectors.

Key Points: 
  • Stronghold continues to vigilantly manage its exposure to counterparties exposed to the cryptocurrency and technology sectors.
  • During the first quarter of 2023, Stronghold earned approximately 618 Bitcoin through its mining operations, an increase of approximately 38% from the 447 Bitcoin mined during the fourth quarter of 2022.
  • As of May 8, 2023, Stronghold’s current Bitcoin mining fleet exceeds 31,000 miners with hash rate capacity of approximately 2.8 EH/s.
  • To access the call by phone, please use the following link Stronghold Digital Mining First Quarter 2023 Earnings Call .